Science to practice
Latest highlights on drug safety and efficacy

12.12.2024

Kidney diseases now affect over 850 million people worldwide, and the numbers are steadily increasing, driven in part by the rising prevalence of diabetes. This growing burden places significant strain on healthcare systems globally (1). 

Despite the growing burden, all hope is not lost. Recent therapeutic advancements, particularly the dual actions of SGLT2 inhibitors and GLP-1 receptor agonists, have shown remarkable improvements in cardiovascular and kidney outcomes. These treatments offer new hope, slowing the progression of kidney disease in people with diabetes and improving their long-term prognosis (2).

For comprehensive insights into drug treatment in renal failure, explore our database Renbase.

New therapies, like SGLT2 inhibitors and GLP-1 receptor agonists, offer hope by slowing kidney disease progression and improving outcomes.

News produced by Medbase Medical Team

References

1. Bello AK, Okpechi IG, Levin A, et al.; ISN-GKHA Group. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024 Mar;12(3):e382-e395. doi: 10.1016/S2214-109X(23)00570-3. PMID: 38365413.
2. Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024 Aug;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4. Epub 2024 Jul 8. PMID: 38991584.